Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 18 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors at 4 institutions in 1 country.
Tatsuhiko OzawaDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.ORCID 0000-0002-3112-452X
Hideki TaniDepartment of Virology, Toyama Institute of Health, Toyama, Japan.ORCID 0000-0002-6309-277X
Yuki AnrakuFaculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-5731-0902
Shunsuke KitaFaculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID 0000-0003-3969-302X
Emiko IgarashiDepartment of Virology, Toyama Institute of Health, Toyama, Japan.
Yumiko SagaDepartment of Virology, Toyama Institute of Health, Toyama, Japan.
Noriko InasakiDepartment of Virology, Toyama Institute of Health, Toyama, Japan.
Hitoshi KawasujiDepartment of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Hiroshi YamadaDepartment of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.ORCID 0000-0001-6678-2701
So-Ichiro SasakiSection of Host Defences, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Japan.
Mayu SomekawaDepartment of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.ORCID 0000-0002-5923-2530
Jiei SasakiLaboratory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Yoshihiro HayakawaSection of Host Defences, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Japan.ORCID 0000-0002-7921-1171
Yoshihiro YamamotoDepartment of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.ORCID 0000-0003-2088-8724
Yoshitomo MorinagaDepartment of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.ORCID 0000-0002-3827-6411
Nobuyuki KurosawaDepartment of Life Sciences and Bioengineering, Laboratory of Molecular and Cellular Biology, Faculty of Engineering, Academic Assembly, University of Toyama, Toyama, Japan.ORCID 0000-0002-1548-4541
Masaharu IsobeDepartment of Life Sciences and Bioengineering, Laboratory of Molecular and Cellular Biology, Faculty of Engineering, Academic Assembly, University of Toyama, Toyama, Japan.ORCID 0000-0003-1864-9273
Hideo FukuharaFaculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-7035-8206
Katsumi MaenakaFaculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-5459-521X
Takao HashiguchiLaboratory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.ORCID 0000-0001-7578-7571
Hiroyuki KishiDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.ORCID 0000-0002-8740-5371
Hideki NiimiDepartment of Clinical Laboratory and Molecular Pathology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.ORCID 0000-0002-6838-5846
University of Toyama · JPHokkaido University · JPToyama Institute of Health · JPKyoto University · JP
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. · full record | OpenQuestion